Does Rallies show 13F holders for LXEO?

Yes. Rallies tracks hedge fund and 13F ownership data for LXEO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is LXEO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LXEO. It does not provide personalized investment advice.

LXEO (Lexeo Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Lexeo Therapeutics, Inc. Common Stock (LXEO) is a publicly traded Healthcare sector company. As of May 21, 2026, LXEO trades at $5.34 with a market cap of $369.84M and a P/E ratio of -2.67. LXEO moved +14.51% today. Year to date, LXEO is -45.76%; over the trailing twelve months it is +45.04%. Its 52-week range spans $1.45 to $11.72. Analyst consensus is strong buy with an average price target of $18.60. Rallies surfaces LXEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns LXEO stock?

Hedge funds tracked by Rallies that own LXEO include Orbimed Advisors, D1 Capital, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Lexeo Therapeutics, Inc. Common Stock.

LXEO Key Metrics

Key financial metrics for LXEO
Metric	Value
Price	$5.34
Market Cap	$369.84M
P/E Ratio	-2.67
EPS	$-1.86
Dividend Yield	0.00%
52-Week High	$11.72
52-Week Low	$1.45
Volume	10
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-99.96M
Gross Margin	0.00%

Top Hedge Funds Holding LXEO

Orbimed Advisors holds 3.60M shares of LXEO, changed +69.53% as of Mar 31, 2026.
D1 Capital holds 978.65K shares of LXEO, changed +0.00% as of Sep 30, 2025.
Panagora Asset holds 34.30K shares of LXEO, changed +0.00% as of Mar 31, 2026.

Latest LXEO News

Lexeo Unveils Porcine TNNI3 Model and 10L-200L AAV Scale-Up at ASGCT — Apr 27, 2026
Lexeo’s LX2006 Shows LVMI, Troponin Declines; LX2020 Cuts VT by 60% — Feb 28, 2026
Lexeo Details 30% LV Mass Reduction, FDA OKs Pooled Phase I/II for LX2006 — Feb 14, 2026

Recent LXEO Insider Trades

Townsend Richard Nolan sold 55.00K (~$313.14K) on Apr 6, 2026.
Otero Jose Manuel sold 3.02K (~$19.29K) on Feb 18, 2026.
Townsend Richard Nolan sold 10.17K (~$64.92K) on Feb 18, 2026.

LXEO Analyst Consensus

5 analysts cover LXEO: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $18.60.

Common questions about LXEO

Who owns LXEO stock?: Hedge funds tracked by Rallies that own LXEO include Orbimed Advisors, D1 Capital, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Lexeo Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for LXEO?: Yes. Rallies tracks hedge fund and 13F ownership data for LXEO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is LXEO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LXEO. It does not provide personalized investment advice.